NZ506447A - Peptide analogues of insulin with alanine substitutions and pharmaceutical use - Google Patents

Peptide analogues of insulin with alanine substitutions and pharmaceutical use

Info

Publication number
NZ506447A
NZ506447A NZ506447A NZ50644799A NZ506447A NZ 506447 A NZ506447 A NZ 506447A NZ 506447 A NZ506447 A NZ 506447A NZ 50644799 A NZ50644799 A NZ 50644799A NZ 506447 A NZ506447 A NZ 506447A
Authority
NZ
New Zealand
Prior art keywords
peptide analogues
insulin
pharmaceutical use
alanine substitutions
analogues
Prior art date
Application number
NZ506447A
Other languages
English (en)
Inventor
Amitabh Gaur
Nicholas Ling
Paul J Conlon
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of NZ506447A publication Critical patent/NZ506447A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ506447A 1998-02-23 1999-02-23 Peptide analogues of insulin with alanine substitutions and pharmaceutical use NZ506447A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2815698A 1998-02-23 1998-02-23
PCT/US1999/003915 WO1999042482A1 (en) 1998-02-23 1999-02-23 Methods for treatment of diabetes using peptide analogues of insulin

Publications (1)

Publication Number Publication Date
NZ506447A true NZ506447A (en) 2002-11-26

Family

ID=21841884

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ506447A NZ506447A (en) 1998-02-23 1999-02-23 Peptide analogues of insulin with alanine substitutions and pharmaceutical use

Country Status (20)

Country Link
US (1) US6197926B1 (enExample)
EP (1) EP1056776A1 (enExample)
JP (1) JP2002504491A (enExample)
KR (1) KR20010041238A (enExample)
CN (1) CN1241942C (enExample)
AP (1) AP2000001888A0 (enExample)
AU (1) AU741037B2 (enExample)
BR (1) BR9908178A (enExample)
CA (1) CA2321929A1 (enExample)
EA (1) EA003944B1 (enExample)
HU (1) HUP0100928A3 (enExample)
ID (1) ID26788A (enExample)
IL (1) IL137904A0 (enExample)
NO (1) NO20004198L (enExample)
NZ (1) NZ506447A (enExample)
OA (1) OA11453A (enExample)
PL (1) PL342517A1 (enExample)
SK (1) SK12412000A3 (enExample)
TR (1) TR200003048T2 (enExample)
WO (1) WO1999042482A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562942B1 (en) 1999-02-23 2003-05-13 Neurocrine Biosciences, Inc. Methods for treatment of diabetes using peptide analogues of insulin
CN1125081C (zh) * 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
ATE367816T1 (de) * 2000-05-12 2007-08-15 Univ Oregon Health & Science Verwendung von niedrigen dosen estrogen in kombination mit immunotherapeutischen verbindungen zur behandlung von immunkrankheiten
US20020103131A1 (en) * 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
US20070172453A1 (en) * 2002-08-30 2007-07-26 Vincent Geenen Tolerogenic approach for type 1 diabetes
US20040138116A1 (en) * 2002-08-30 2004-07-15 Vincent Geenen Tolerogenic approach for type 1 diabetes
ZA200502613B (en) 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
JP2006526651A (ja) * 2003-06-02 2006-11-24 マーシア・ファーマ・インコーポレイテッド 1型糖尿病の処置のための治療的ワクチン組成物
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US8481485B2 (en) * 2008-12-19 2013-07-09 Indiana University Research And Technology Corporation Insulin analogs
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
WO2011056226A1 (en) 2009-11-05 2011-05-12 Mercia Pharma Llc Adjuvanted nanoparticulate influenza vaccine
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110311536A1 (en) * 2010-06-11 2011-12-22 Dana-Farber Cancer Institute, Inc. Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8946147B2 (en) 2010-06-24 2015-02-03 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014015156A2 (pt) 2011-12-20 2020-10-27 Indiana University Research And Technology Corporation análogos de insulina à base de ctp, seus métodos de produção e uso no tratamento de hiperglicemia, bem como sequência de ácido nucleico e célula hospedeira
CN108383902A (zh) 2012-09-26 2018-08-10 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
WO2014158900A1 (en) 2013-03-14 2014-10-02 Indiana University Research And Technology Corporation Insulin-incretin conjugates
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
ES2947409T3 (es) 2014-09-24 2023-08-08 Univ Indiana Res & Tech Corp Profármacos de insulina a base de amida lipídica
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN111925420B (zh) * 2019-12-11 2022-04-01 山东大学 一种多肽作为嗅觉受体Olfr109激动剂配体的应用
USD1043348S1 (en) * 2021-09-24 2024-09-24 H.J. Heinz Company Brands Llc Bottle

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5559094A (en) 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5594100A (en) * 1995-02-22 1997-01-14 Regents Of The University Of Colorado Epitope for prevention of type I diabetes
EP0835129B1 (en) * 1995-06-30 2003-10-29 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes

Also Published As

Publication number Publication date
CN1241942C (zh) 2006-02-15
NO20004198L (no) 2000-10-20
NO20004198D0 (no) 2000-08-22
SK12412000A3 (sk) 2002-05-09
JP2002504491A (ja) 2002-02-12
WO1999042482A1 (en) 1999-08-26
TR200003048T2 (tr) 2000-12-21
CA2321929A1 (en) 1999-08-26
HUP0100928A3 (en) 2001-11-28
EA003944B1 (ru) 2003-10-30
EA200000872A1 (ru) 2001-02-26
IL137904A0 (en) 2001-10-31
HUP0100928A2 (hu) 2001-08-28
BR9908178A (pt) 2002-01-15
OA11453A (en) 2003-12-08
US6197926B1 (en) 2001-03-06
KR20010041238A (ko) 2001-05-15
AU2783199A (en) 1999-09-06
AP2000001888A0 (en) 2000-09-30
ID26788A (id) 2001-02-08
CN1294597A (zh) 2001-05-09
AU741037B2 (en) 2001-11-22
PL342517A1 (en) 2001-06-18
EP1056776A1 (en) 2000-12-06

Similar Documents

Publication Publication Date Title
NZ506447A (en) Peptide analogues of insulin with alanine substitutions and pharmaceutical use
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MD960317A (ro) Noile peptide-agoniste ale amilinei şi utilizarea lor
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
NO914085D0 (no) Hepatospesifikke insulinanaloger
TW200626613A (en) Analogues of GLP-1
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
DE69027989D1 (de) Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON
ATE177757T1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
ZA9810679B (en) Antimicrobial peptides.
BR9910639A (pt) Drogas anti-angiogênicas compreendendo peptìdeo
ES2174770T1 (es) Peptidos diseñados para el diagnostico y el tratamiento de artritis reumatoide.
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
GB9606040D0 (en) Active peptide
EP0761684A3 (en) Replacement analogs for magainin peptides containing alanine residue
HU9402909D0 (en) Suppression of t-cell proliferation using peptide fragments of myelin basic protein
IL139604A (en) Fibrinogen-beta chain derived peptide, compositions comprising same and use thereof
JPS53132539A (en) Protected amino acid or peptide having said protected amino acid residue
ECSP961741A (es) Insulina de caneda sencilla con alta bioactividad (
DK119391A (da) Humaninsulinanaloger

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)